Introduction {#sec1-0300060520925644}
============

Bone metastasis is defined as a primary malignant non-hematopoietic cancer transmitted to the skeletal system via the blood or lymph. Cytokines and chemical mediators released from cancer cells stimulate the periosteum, increase mechanical pressure on the bone, and generate osteolytic lesions, leading to serious bone pain. Bone metastases may be associated with various skeletal-related events (SREs), including pathological fractures, spinal cord compression, and hypercalcemia of malignancy, requiring surgical intervention and/or palliative radiotherapy.^[@bibr1-0300060520925644]^ The occurrence of SREs significantly decreases the patient's quality of life and increases the risks of morbidity and mortality.^[@bibr2-0300060520925644]^ Bone metastases are the most common distant metastases, occurring in about 15% to 40% of patients with lung cancer, and are associated with shorter survival compared with metastases to other systems.^[@bibr3-0300060520925644]^,^[@bibr4-0300060520925644]^ Moreover, improvements in the treatment of lung cancer have prolonged the median survival time, thus increasing the risk of bone metastases during the patient's remaining lifetime.

Non-small cell lung cancer (NSCLC) accounts for about 85% to 90% of all lung cancers.^[@bibr5-0300060520925644]^ The early diagnosis and prevention of bone metastases are therefore important and can increase the survival rate of patients with NSCLC. An evaluation of the relevant prognostic factors is necessary to ensure the optimal prevention of and precise therapy for bone metastases from NSCLC.^[@bibr6-0300060520925644]^ However, the independent prognostic factors for bone metastases from NSCLC remain unclear, and relevant studies are scarce and controversial.^[@bibr2-0300060520925644][@bibr3-0300060520925644][@bibr4-0300060520925644][@bibr5-0300060520925644][@bibr6-0300060520925644]--[@bibr7-0300060520925644]^ In this retrospective study, we investigated the clinical features and evaluated the prognostic factors in patients with bone metastases from NSCLC.

Patients and methods {#sec2-0300060520925644}
====================

Patients {#sec3-0300060520925644}
--------

We retrospectively investigated patients with NSCLC with bone metastases treated at Qingpu Branch of Zhongshan Hospital from January 2012 to December 2017. All patients had a histological or cytological diagnosis of NSCLC. The diagnosis of bone metastasis was confirmed by positive results of more than two examinations, including X-ray, computed tomography, magnetic resonance imaging, radionuclide bone scan, and positron emission tomography.

Clinical features {#sec4-0300060520925644}
-----------------

Multiple clinical variables were evaluated as potential prognostic factors, including age, sex, number of primary lesions, histological type, number of bone metastases, smoking history, Eastern Cooperative Oncology Group performance status (ECOG PS), surgery for primary lesions, chemotherapy, radiotherapy, and bisphosphonate therapy. We also assessed serum concentrations of biochemical and biological markers, including calcium, sodium, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125), and carbohydrate antigen 199 (CA199). According to standard laboratory values, hyponatremia was defined as a serum sodium level \<135 mmol/L and hypercalcemia as a serum calcium level ≥2.4 mmol/L. The following upper cut-off values were applied: LDH 225 U/L, ALP 140 U/L, CEA 5 ng/mL, CYFRA21-1 3 ng/mL, NSE 20 ng/mL, CA125 35 U/mL, and CA199 27 U/mL.

Statistical analysis {#sec5-0300060520925644}
--------------------

Statistical analysis was performed using IBM SPSS Statistics for Windows, version 21.0 (IBM Corp., Armonk, NY, USA). The overall survival (OS) and 1-year survival rate were calculated using the Kaplan--Meier method. OS was defined as the time from diagnosis of bone metastasis to the date of death or the last follow-up.^[@bibr6-0300060520925644]^ Survival differences were compared by univariate analysis using the log-rank test. Independent prognostic factors were identified by multivariate analysis using the Cox proportional hazards model. Odds ratios and 95% confidence intervals were calculated. A *P* value \< 0.05 was considered to be statistically significant.

This study was approved by Zhongshan Hospital Ethics Committee and all procedures were conducted in accordance with the Declaration of Helsinki. All participants signed written informed consent.

Results {#sec6-0300060520925644}
=======

A total of 356 patients with NSCLC with bone metastases were included in the study, including 213 men and 143 women. Their median age was 53 years (range 23--89 years) and 252 patients were aged 50 years or older. Based on the histological classification, 203 patients were identified as having adenocarcinoma, 98 squamous cell carcinoma, and 55 not otherwise specified (NOS). A total of 694 sites of bone metastases were determined, including 401 in patients with adenocarcinoma, 234 for squamous cell carcinoma, and 59 for NOS. The most common site of bone metastases was the ribs (n = 186), followed by the thoracic (n = 147) and lumbar spine (n = 116). The least affected site was the tibia/fibula ([Table 1](#table1-0300060520925644){ref-type="table"}).

###### 

Sites of bone metastases for different histological types of non-small cell lung cancer.

![](10.1177_0300060520925644-table1)

  Histology          Adenocarcinoma   Squamous   NOS   
  ------------------ ---------------- ---------- ----- -----
  Skull              12               7          4     23
  Scapula            15               11         2     28
  Clavicle           9                4          2     15
  Rib                109              60         17    186
  Humerus            11               8          0     19
  Cervical spine     29               11         5     45
  Thoracic spine     86               50         11    147
  Lumbar spine       58               45         13    116
  Pelvis             45               29         5     79
  Femur              23               8          0     31
  Tibia and fibula   4                1          0     5
  Total              401              234        59    694

NOS: not otherwise specified.

A total of 187 patients were former or current smokers. Most patients (n = 267) had an ECOG PS \> 2. At the time of diagnosis, 225 patients had bone metastases at more than two sites and 131 patients had single bone lesions. The median OS was 12.5 months and the 1-year survival rate was 50.8%. The correlations between clinical factors and OS are summarized in [Table 2](#table2-0300060520925644){ref-type="table"}. Univariate analysis identified histological type (*P* = 0.019), number of bone metastases (*P* = 0.005), ECOG PS (*P* \< 0.001), bisphosphonate therapy (*P* = 0.041), serum calcium (*P* = 0.037), LDH (*P* = 0.009), and ALP (*P* = 0.009) as factors significantly correlated with prognosis ([Table 2](#table2-0300060520925644){ref-type="table"}). Multivariate analysis confirmed that multiple bone metastases, ECOG PS ≥2, LDH ≥225 U/L, and ALP ≥140 U/L were independent negative prognostic factors. The risks of multiple bone metastases and ECOG PS ≥2 were 2.169 times (*P* = 0.009) and 1.967 times (*P* = 0.006) greater than the risks of single bone metastasis and ECOG PS \< 2, respectively. Patients with high serum LDH levels and ALP levels had 1.194-fold (*P* = 0.025) and 1.383-fold (*P* = 0.013) increased risks of shorter OS, respectively. Despite the positive findings in univariate analysis, histological type was not a significant independent prognostic factor in multivariate analysis ([Table 3](#table3-0300060520925644){ref-type="table"}).

###### 

Characteristics of patients with bone metastases from non-small cell lung cancer and univariate analysis of prognostic factors.

![](10.1177_0300060520925644-table2)

  Clinical factor              Number of patients   Median OS (months)   1-year survival rate (%)   *P* value
  ---------------------------- -------------------- -------------------- -------------------------- -----------
  Total                        356                  12.5                 50.8                       
  Sex                                                                                               
   Male                        213                  13.6                 48.5                       0.692
   Female                      143                  11.9                 52.9                       
  Age (years)                                                                                       
   \<50                        104                  13.8                 55.9                       0.782
   ≥50                         252                  11.2                 49.9                       
  Number of primary lesions                                                                         
   Single                      276                  13.2                 56.3                       0.753
   Multiple                    80                   5.3                  30.1                       
  Histology                                                                                         
   Adenocarcinoma              203                  8.4                  34.2                       0.019
   Squamous                    98                   13.5                 56.1                       
   NOS                         55                   11.6                 48.3                       
  Number of bone metastases                                                                         
   Single                      131                  14.2                 70.1                       0.005
   Multiple                    225                  7.2                  45.2                       
  Smoking history                                                                                   
   Yes                         187                  11.2                 46.7                       0.573
   No                          169                  13.9                 55.3                       
  ECOG PS                                                                                           
   \<2                         89                   13.4                 63.2                       \<0.001
   ≥2                          267                  4.3                  25.4                       
  Surgery for primary lesion                                                                        
   Yes                         210                  13.1                 57.5                       0.289
   No                          146                  8.2                  45.2                       
  Chemotherapy                                                                                      
   Yes                         264                  14.9                 53.2                       0.365
   No                          92                   9.4                  46.5                       
  Radiotherapy                                                                                      
   Yes                         229                  14.2                 55.9                       0.226
   No                          127                  10.5                 48.6                       
  Bisphosphonate therapy                                                                            
   Yes                         275                  14.5                 65.6                       0.041
   No                          81                   8.1                  45.1                       
  Calcium (mmol/L)                                                                                  
   \<2.4                       78                   14.8                 59.5                       0.037
   ≥2.4                        278                  8.2                  31.8                       
  Sodium (mmol/L)                                                                                   
   \<135                       201                  11.3                 50.4                       0.85
   ≥135                        155                  14.8                 46.2                       
  LDH (U/L)                                                                                         
   \<225                       112                  15.7                 57.7                       0.009
   ≥225                        244                  8.8                  35.3                       
  ALP (U/L)                                                                                         
   \<140                       111                  15.6                 59.2                       0.008
   ≥140                        245                  8.2                  24.3                       
  CEA (ng/ml)                                                                                       
   \<5                         104                  13.8                 55.2                       0.242
   ≥5                          252                  11.7                 49.4                       
  CYFRA21-1(ng/mL)                                                                                  
   \<3                         95                   14.4                 53.6                       0.176
   ≥3                          261                  10.6                 50.2                       
  NSE (ng/mL)                                                                                       
   \<20                        188                  12.2                 54.3                       0.454
   ≥20                         168                  11.4                 47.6                       
  CA125 (U/mL)                                                                                      
   \<35                        99                   14.9                 53.5                       0.259
   ≥35                         257                  11.4                 42.6                       
  CA199 (U/mL)                                                                                      
   \<37                        137                  14.3                 53.2                       0.672
   ≥37                         219                  11.7                 47.3                       

OS, overall survival; NOS, not otherwise specified; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; CYFRA, cytokeratin 19 fragment; NSE, non-specific enolase; CA, carbohydrate antigen.

###### 

Multivariate analysis of potential prognostic factors in patients with bone metastases from non-small cell lung cancer.

![](10.1177_0300060520925644-table3)

  Clinical factor               OR      95% CI         *P* value
  ----------------------------- ------- -------------- -----------
  Histological type                                    
   Adenocarcinoma vs squamous   1.629   1.216--1.975   0.238
   Squamous vs NOS              0.752   0.534--0.891   0.375
   Adenocarcinoma vs NOS        1.376   1.021--1.774   0.417
   Multiple bone metastases     2.169   1.217--3.985   0.009
   ECOG PS ≥2                   1.967   1.126--2.493   0.006
   Bisphosphonate therapy       0.908   0.560--1.236   0.273
   Calcium ≥2.4 mmol/L          0.872   0.327--1.149   0.169
   LDH ≥225 U/L                 1.194   0.515--1.533   0.025
   ALP ≥140 U/L                 1.383   0.932--1.951   0.013

OR, odds ratio; CI: confidence interval; NOS, not otherwise specified; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ALP, alkaline phosphatase.

Discussion {#sec7-0300060520925644}
==========

This study found that the ribs and thoracolumbar spine, which are relatively close to the lungs, were the most common sites of bone metastases from NSCLC. Cancer cells mainly spread via the blood circulation, and the bones of the trunk are rich in red bone marrow, with abundant capillary vessels. With intercostal and vertebral vein branches, the ribs and thoracolumbar spine provide favorable conditions for the colonization and proliferation of cancer cells, which express high levels of adhesion molecules. Metastases may thus occur in the bones of the trunk at an early stage, followed by the limb bones at more advanced stages.^[@bibr8-0300060520925644]^ In the current study, adenocarcinoma was associated with the highest incidence of bone metastases, possibly because it often occurs in the margins of the lung, making it easy for the cancer cells to invade the blood system at an early stage.

The relationship between lung cancer histology and the risk of bone metastasis is controversial. Different histological types have shown distinct prevalence and heterogeneity in relation to bone metastases. Oliveira et al.^[@bibr9-0300060520925644]^ revealed that adenocarcinoma was associated with a higher risk and squamous cell carcinoma with a lower risk of bone metastases, while Zhang et al.^[@bibr10-0300060520925644]^ also suggested that adenocarcinoma had a poorer prognosis than other histological types. However, squamous cell carcinoma has also been associated with a bad prognosis,^[@bibr11-0300060520925644]^ and patients with non-adenocarcinoma were documented as being more likely to have SRE throughout the course of NSCLC.^[@bibr12-0300060520925644]^ Wang et al.^[@bibr13-0300060520925644]^ reported that patients with adenocarcinoma were prone to bone metastases and that squamous cell carcinoma had a poor prognosis. However, the current results indicated that histological type was not an independent prognostic factor for OS in multivariate analysis. This may be because recent epidermal growth factor receptor mutation-targeted therapies have prolonged the survival time, especially in patients with adenocarcinoma, who tend to have a higher incidence of this mutation.^[@bibr7-0300060520925644]^,^[@bibr14-0300060520925644]^

The results of the current study were consistent with previous studies, revealing that the number of bone metastases and ECOG PS have significant impacts on survival time in patients with NSCLC.^[@bibr15-0300060520925644]^,^[@bibr16-0300060520925644]^ Multiple bone metastases often indicate high activity and malignancy of cancer cells, while the ECOG PS is the standard criterion for measuring the impact of cancer on the patient's daily activity and physical ability. Patients with a high ECOG PS have generally poor health and are intolerant to high-intensity radiotherapy and chemotherapy.^[@bibr10-0300060520925644]^ Multiple bone metastases and a high ECOG PS are therefore associated with a poor prognosis.

The bone structure is maintained by the dynamic balance between bone resorption and formation. Bone metastases disrupt this balance and stimulate bone formation. ALP, as an indicator of osteoblastic activity, is produced by the bone and liver, and serum ALP levels indicating bone formation are elevated in lung cancer patients with osteolytic metastases, providing a potentially useful predictor of bone metastases.^[@bibr17-0300060520925644]^ LDH is an important enzyme associated with glycolysis, which is increased by bone metastases. Previous studies revealed that high serum levels of ALP and LDH were negative prognostic factors for bone metastases in patients with small cell lung cancer,^[@bibr18-0300060520925644]^,^[@bibr19-0300060520925644]^ and the current study demonstrated similar results for NSCLC.

Bisphosphonate therapy has been strongly recommended to prevent or delay the development of SREs in patients with NSCLC with bone metastasis.^[@bibr20-0300060520925644]^ Izumi et al.^[@bibr21-0300060520925644]^ indicated that zoledronate-related fever was associated with improved OS. Hypercalcemia is usually accompanied by SREs at an advanced stage of lung cancer, and is a predictive factor for the occurrence of SREs.^[@bibr22-0300060520925644]^ In the current study, bisphosphonate therapy and hypercalcemia were both significant factors affecting OS according to univariate analysis; however, their significance was not retained in multivariate analysis, and they may thus be regarded as potential prognostic factors.

This study was limited by being a retrospective, single-center, observational study with a short follow-up interval, which was therefore susceptible to bias in terms of data collection and analysis. Further, large-scale prospective multi-center studies are therefore warranted to confirm the current findings.

Conclusion {#sec8-0300060520925644}
==========

According to the current study, the ribs and thoracolumbar spine are the preferred sites of bone metastases from NSCLC, while multiple bone metastases, high ECOG PS, and high serum ALP and LDH levels are independent negative prognostic factors for bone metastases from NSCLC. Further studies are needed to verify the current findings, with the aim of establishing a predictive model for bone metastases from NSCLC.
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